Condition: Non-hodgkin Lymphoma · Sponsor: Canadian Cancer Trials Group
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).
This description comes directly from the study's public registry record.
Annette Hay · 613-533-6430 · ahay@ctg.queensu.ca
Always discuss trial participation with your own doctor first.
| Arthur J.E. Child Comprehensive Cancer Centre | Calgary, Alberta, Canada | Recruiting |
| BCCA - Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton, Ontario, Canada | Recruiting |
| Ottawa Hospital Research Institute | Ottawa, Ontario, Canada | Recruiting |
| University Health Network | Toronto, Ontario, Canada | Recruiting |
| The Research Institute of the McGill University | Montreal, Quebec, Canada | Recruiting |
| CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) | Québec, Quebec, Canada | Recruiting |
| Allan Blair Cancer Centre | Regina, Saskatchewan, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05998642